Table 7.
Risk features of myelofibrosis in MDS patients underwent HSCT by Cox regression analysis (n = 141)
| Variable | Relapse | NRM | DFS | OS | ||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |
| P | P | P | P | |||||
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |||||
| Age | 0.988 | – | 0.169 | – | 0.21 | – | 0.21 | – |
| 1.00 (0.96–1.04) | 1.02 (0.99–1.05) | 1.02 (0.99–1.04) | 1.02 (0.99–1.04) | |||||
| Sex | – | – | – | – | ||||
| Male | Ref. | Ref. | Ref. | Ref. | ||||
| Female | 0.566 | 0.304 | 0.245 | 0.319 | ||||
| 0.76 (0.30–1.93) | 0.70 (0.36–1.38) | 0.72 (0.42–1.25) | 0.74 (0.41–1.34) | |||||
| Cytogenetics | ||||||||
| Non–complex karyotypes | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| Complex karyotypes | 0.012 | 0.006 | 0.328 | 0.347 | 0.012 | 0.020 | 0.014 | 0.009 |
| 3.51 (1.32–9.34) | 4.16 (1.51–11.45) | 1.51 (0.66–3.46) | 1.51 (0.64–3.55) | 2.24 (1.19–4.20) | 2.16 (1.13–4.12) | 2.28 (1.18–4.42) | 2.47 (1.25–4.90) | |
| BM blasts at HSCT | ||||||||
| ≤ 5% | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| > 5% | 0.349 | 0.253 | 0.343 | 0.245 | 0.782 | 0.773 | 0.763 | 0.73 |
| 1.80 (0.53–6.20) | 2.08 (0.59–7.31) | 0.72 (0.36–1.43) | 0.66 (0.33–1.33) | 0.92 (0.51–1.66) | 0.92 (0.51–1.66) | 0.91 (0.48–1.72) | 0.89 (0.47–1.69) | |
| Myelofibrosis | ||||||||
| MF = 0/1 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| MF = 2/3 | 0.964 | 0.914 | 0.986 | 0.286 | 0.459 | 0.396 | 0.569 | 0.444 |
| 0.97 (0.28–3.34) | 1.07 (0.31–3.76) | 1.02 (0.13–8.15) | 0.56 (0.20–1.62) | 0.74 (0.34–1.64) | 0.71 (0.32–1.58) | 0.78 (0.33–1.84) | 0.71 (0.30–1.70) | |
| Time to HSCT from diagnosis | ||||||||
| ≤ 6 months | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| > 6 months | 0.77 | 0.888 | 0.56 | 0.709 | 0.952 | 0.678 | 0.741 | 0.526 |
| 0.86 (0.31–2.39) | 1.08 (0.38–3.08) | 0.63 (0.13–3.02) | 1.15 (0.56–2.34) | 1.02 (0.58–1.80) | 1.13 (0.63–2.04) | 1.11 (0.60–2.04) | 1.23 (0.65–2.31) | |
| Previous therapy for MDS | ||||||||
| No cytoreductive treatments | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
| Cytoreductive treatments | 0.468 | 0.327 | 0.337 | 0.642 | 0.902 | 0.856 | 0.794 | 0.627 |
| 1.41 (0.56–3.60) | 1.61 (0.62–4.19) | 1.97 (0.49–7.89) | 0.86 (0.45–1.64) | 0.97 (0.57–1.63) | 1.05 (0.62–1.79) | 1.08 (0.61–1.91) | 1.16 (0.64–2.07) | |
| Donor source | ||||||||
| HID | Ref | – | Ref | – | Ref | – | Ref | – |
| MUD | 0.806 | 0.277 | 0.709 | 0.903 | ||||
| 0.77 (0.09–6.50) | 2.49 (0.48–12.81) | 0.82 (0.28–2.37) | 1.07 (0.37–3.13) | |||||
| MSD | 0.393 | 0.374 | 0.646 | 0.717 | ||||
| 1.54 (0.57–4.11) | 0.48 (0.09–2.45) | 0.88 (0.51–1.51) | 0.90 (0.50–1.62) | |||||
| Stem cell source | ||||||||
| PB | Ref | – | Ref | – | Ref | – | Ref | – |
| PB + BM | 0.325 | 0.628 | 0.899 | 0.666 | ||||
| 1.60 (0.63–4.07) | 0.85 (0.45–1.62) | 1.03 (0.61–1.74) | 1.13 (0.64–2.00) | |||||
NRM non-replase mortality, RI relapse incidence, DFS disease-free survival, OS overall survival (after allo-HSCT), MF myelofibrosis